Preferred Label : Anti-CD73 Monoclonal Antibody BMS-986179;
NCIt related terms : BMS-986179;
NCIt definition : A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation
73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and
antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody BMS-986179
targets and binds to CD73, leading to clustering and internalization of CD73. This
prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to
adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated
suppression of lymphocyte activity and increases the activity of CD8-positive effector
cells. This also activates macrophages, and reduces the activity of both myeloid-derived
suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory
effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response
against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein
belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer
cell types and catalyzes the conversion of extracellular nucleotides, such as AMP,
to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated
immunosuppression within the tumor microenvironment.;
UNII : 7PO9B4VQ1U;
Molecule name : BMS-986179; BMS 986179;
NCI Metathesaurus CUI : CL520363;
Origin ID : C132266;
UMLS CUI : C4329317;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
